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Infants born to human immunodeficiency virus (HIV) infected women are HIV-exposed 
but the majority remains uninfected [i.e., HIV-exposed uninfected (HEU)]. HEU infants 
suffer greater morbidity and mortality from infections compared to HIV-unexposed (HU) 
peers. The reason(s) for these worse outcomes are uncertain, but could be related to 
an altered immune system state. This review comprehensively summarizes the current 
literature investigating the adaptive and innate immune system of HEU infants. HEU 
infants have altered cell-mediated immunity, including impaired T-cell maturation with 
documented hypo- as well as hyper-responsiveness to T-cell activation. And although 
prevaccination vaccine-specific antibody levels are often lower in HEU than HU, most 
HEU infants mount adequate humoral immune response following primary vaccination 
with diphtheria toxoid, haemophilus influenzae type b, whole cell pertussis, measles, hep-
atitis B, tetanus toxoid, and pneumococcal conjugate vaccines. However, HEU infants 
are often found to have lower absolute neutrophil counts as compared to HU infants. 
On the other hand, an increase of innate immune cytokine production and expression 
of co-stimulatory markers has been noted in HEU infants, but this increase appears to 
be restricted to the first few weeks of life. The immune system of HEU children beyond 
infancy remains largely unexplored.
Keywords: Hiv, Hiv-exposed infants, innate immune system, cell-mediated immune system, humoral immune 
response
iNTRODUCTiON
Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) has been reduced 
from 14–48% (1) to less than 3% in both high-income countries (2–4) and resource-limited settings 
(5, 6). The vast majority of infants born to HIV-infected women, thus, are HIV-exposed uninfected 
(HEU). In countries with high prevalence of HIV infection, such as some parts of Sub-Saharan 
Africa, HEU infants can comprise a significant proportion reaching 30% of all infants (6).
The mortality rates of HEU infants are twice higher than HIV-unexposed (HU) peers in the 
second year of life in Zimbabwe (7), 4.6% through 4 months in Zambia (8), and 4.9% by 1 year in 
Africa (9). This relates in part to the elevated risk of HEU infants suffer from infectious disease; this 
is the case in both low- (10, 11) and high-income countries (12). Specifically, increased risk for con-
tracting infections (13), higher risk for severity of infection (14–18), greater rates of hospitalization 
(15, 18), and mortality (7) have been documented in HEU as compared to HU infants. HEU infants 
appear particularly susceptible to invasive infection with Group B Streptococcus and Streptococcus 
pneumoniae invasive disease as well respiratory tract infections (14, 19, 20).
2Abu-Raya et al. The Immune System of HIV-Exposed Uninfected Infants
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 383
The underlying cause of the increased risk for infectious 
morbidity and mortality in HEU remains unknown, thus, 
can currently not be rectified. HEU infants have two unique 
exposures compared to their HU peers that have the potential to 
alter their developing immune system and with that potentially 
worsen their infectious disease outcomes: antiretroviral (ARV) 
drugs and maternal HIV infection (21). Some of the ARV drugs, 
such as zidovudine (ZDV), have mitochondrial toxicity likely 
due to inhibition of host cell gamma-polymerase and accu-
mulation of somatic mitochondrial DNA mutations (22,  23), 
or due to direct interference with mitochondrial bioenergetics 
cascades (24, 25), and induction of reactive oxygen species 
formation leading to cell damage (26). In vitro studies have 
revealed that ZDV exposure inhibits hematopoietic progenitor 
cells, which may explain ARV’s associated decreased red blood 
cell, neutrophil, and lymphocyte counts (27, 28). ZDV also 
has the potential to impair the HEU infant’s innate immune 
system development (specifically granulocytes/macrophages) 
(27). Combination ARV therapy has been associated with larger 
and longer lasting suppressive effect on neonatal neutrophil and 
lymphocyte counts at age of 0–2 months as compared to ARV 
mono-therapy (28).
Even when the neonate escapes HIV infection, the HIV-
infected maternal–fetus interface may present an altered 
environment for fetal growth and development. HIV-infected 
women are at increased risk for chorioamnionitis and deciduitis 
(29). Increased infection or inflammation of the uterine environ-
ment exposes the developing immune system of the neonate to 
antigens and a potentially pro-inflammatory milieu of cytokines 
and chemokines. It is also noteworthy that the vaginal microbiota 
appears to be altered in HIV-infected women (30), which may 
be of importance for early infancy colonization with microbes. 
The sum of these effects is conceptualized as an “active womb” of 
HIV-infected women that has the potential to prime and alter the 
development of the neonatal immune system.
We here review what is known about altered function (both 
adaptive and innate) during early life immune ontogeny of HEU 
infants.
ADAPTive iMMUNe SYSTeM  
OF HeU iNFANTS
Cell-Mediated immunity of HeU infants
Previous studies described both the quantitative and functional 
measures of the cell-mediated immunity (CMI) of HEU infants. 
Data on the quantity and quality (function) of CMI among HEU 
infants are derived mainly from observational studies. Moreover, 
these studies are difficult to interpret and their results are incon-
sistent, challenging the ability to draw a definite conclusion. This 
is further complicated by variability of the cohort characteristics 
reported (age at enrollment, settings, ethnicity, time span of 
follow-up) and laboratory methodology (antigenic stimulus, 
functional test) utilized.
T-Cell Subsets of HEU Infants
The most reported immunological abnormality of HEU infants 
pertains to the frequency of immune cell subsets. Cluster of 
differentiation (CD) 4 T-cells have been relatively well studied 
in HEU infants, owing to both the vulnerability of CD4 T-cells 
to HIV infection and their important role as regulators of the 
immune system and acquired immunity. Lower CD4 T-cell 
counts (28, 31–37) and to a lesser extent lower CD8 T-cell counts 
(32, 33) have been reported in multiple studies contrasting HEU 
infants to HU peers. Maternal HIV viral load has been proposed 
as a correlate for subsequent HEU T-cells counts. At 2 and 
6 months of age, HEU infants born to mothers with viral load 
>1000 copies/ml had lower CD4 T-cell counts compared to HEU 
infants born to mothers with viral load <50 copies/ml at the time 
of delivery (35). Decreased counts of circulating CD4 T-cells may 
limit antigenic coverage and subsequent response, eventually 
cumulating in increased severity of infections.
However, differences between HEU vs. HU T-cell counts may 
be more nuanced. It has been proposed that the difference in 
the quantity of circulating T-cells detected in HEU infants is in 
part due to difference in frequencies of subsets of CD4 T-cells. 
HEU newborns had lower CD4 to CD8 T-cell ratio, lower CD4 
naïve, and CD8 naïve T-cell percentages, increased percentage 
of activated (CD8+ CD38bright) CD8 T-cells and memory (CD4+ 
CD45RO+) T-cells, augmented double-negative (CD3+ CD4− 
CD8−) and immature (CD4− CD8− CD5− CD44+) T-cells 
when compared to HU newborns (34). The elevated number of 
immature (CD4− CD8− CD5− CD44+) T-cells suggests that the 
physiologic thymic maturation pathway may be impaired in HEU 
children (34). In another study, activated (CD4+ HLA− DR+ 
CD38+) and memory (CD4+ CD45RA− RO+) T-cells were 
higher among HEU infants compared to infants born to HIV-
uninfected women (38). The increase in the percentage of acti-
vated and memory T-cells and the diminished numbers of naïve 
T-cells suggests that this subset of lymphocytes had experienced 
antigenic exposure that could have resulted from either in utero 
exposure of the fetus to antigens or to non-antigen specific cell 
differentiation.
The altered numbers and subtypes of T-cells in HEU infants 
may or may not result in impaired T-cell immune function (21).
T-Cell Function of HEU Infants
Several studies have shown that HEU infants express altered 
CMI function and display impaired T-cell maturation. The CMI 
response of HEU infants has been studied primarily by measuring 
cytokine production and cell proliferation to both HIV-specific 
and non-HIV-specific antigens with reports of hyper- or hypo-
activity depending on the stimulant (Table 1). It is proposed that 
increased CMI response in HEU infants may result from in utero 
exposure to HIV antigens and/or other antigens related to other 
infections in the HIV-infected mothers. By contrast, attenuation 
of the CMI response might be related to limited CD4 T-cells rep-
ertoire and progenitor cell dysfunction that might lead to T-cells 
with compromised function.
HIV-Specific T-Cell Response
It has been fairly well established that following exposure to HIV 
antigens, cytotoxic T lymphocyte responses can be elicited among 
HEU children aged 2–35  months (45–48). Following stimula-
tion with HIV peptides, the production of interleukin (IL)-2 
TAble 1 | Function of cell-mediated immune system of Hiv-exposed 
uninfected infants.
Stimuli types Main functional results
Hiv-specific
HIV antigens Cytokine production:
 – Production of IL-2 by cord blood leukocytes 
(39, 40).
Cellular proliferation:
 – No cellular proliferative response of cord 
blood mononuclear cells (41).
Non-Hiv specific
Staphylococcus aureus 
Cowan
Cytokine production:
 – Reduced cord blood mononuclear cell 
production of IL-12 when compared to 
infants born to HIV negative mothers (42).
PHA Cytokine production:
 – Reduced IL-2 production when compared to 
HU infants (38).
BCG Cellular proliferation:
 – No difference in proliferative response at 
2 weeks when compared to HU infants (36).
 – Weaker proliferative response at 6–8 months 
(43) and at 10 weeks of life (36) when 
compared to HU infants.
 – Stronger proliferative response at 6 and 
14 weeks of life (44) when compared to HU 
infants.
Anti-CD3 and anti-CD28 Cellular proliferation:
– Higher proliferative response when 
compared to HU infants (41).
Staphylococcal 
enterotoxin B
Cellular proliferation:
– Increased proliferative responses at 6 and 
14 weeks of life when compared to HU 
infants (44)
HIV, human immunodeficiency virus; IL, interleukin; IFN, interferon; CD, cluster of 
differentiation; PHA, phytohemagglutinin; BCG, Bacillus Calmette–Guérin; HU, HIV-
unexposed.
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in mononuclear cells was also observed. Specifically, HEU cord 
blood leukocytes produced IL-2 following stimulation with HIV 
antigen in 40–42% of HEU infants (39, 40). However, limited data 
suggest that cord blood mononuclear cells of HEU newborns fail 
to proliferate in response to synthetic HIV envelope peptides 
(41). The clinical significance of these findings thus is currently 
unclear as IL-2 has the potential to promote the expansion and 
influence the differentiation of effector CD4 T-cells into different 
subtypes: Th1, Th2, Th17, and T regulatory cells (49). While the 
aforementioned studies (45–48) may suggest that HEU infants 
have protective CMI responses to HIV, functionally this may not 
translate into effective protection. CD4 T-cells from HEU infants 
that were infected in  vitro with HIV had higher levels of p24 
protein as compared to healthy controls (50). This suggests that 
CD4 T-cells of HEU infants could in fact be more susceptible to 
in vitro HIV infection as compared to healthy controls (50).
Non-HIV-Specific T-Cell Response
While HIV-specific responses are of interest when considering 
MTCT and immunity to HIV, more traditional investigation 
of immune function has relied on generic stimuli to elicit CMI 
responses. In response to Staphylococcus aureus Cowan stimula-
tion, infants of HIV-infected mothers had reduced cord blood 
mononuclear cell production of IL-12, a key Th1-response sup-
porting cytokine, when compared to infants born to HIV-negative 
mothers (42). This suggests a possible suppressive effect of HIV 
exposure on Th1 immunity. However, in response to another 
polyclonal stimulus [phytohemagglutinin (PHA)], reduced IL-2 
has been observed among HEU infants (38) as compared to HU 
infants. In the latter study, a stronger production of IFN-γ to IL-10 
(the ratio of PHA-stimulated IFN-γ to IL-10 production) of cord 
blood cells was observed among HEU than HIV-infected infants 
(51). No HIV-infected infant produced more IFN-γ than IL-10, 
while 43% of HIV-uninfected infants produced higher IFN-γ than 
IL-10 (51). It is important to note that these stimuli activated cells 
via different, and often poorly understood mechanisms (52–59).
Studies have used different methods, culture techniques, 
timing, and stimuli for assessing HEU T-cell proliferation with 
evidence of both hypo and hyper proliferation. Higher lym-
phoproliferative responses to polyclonal T-cell activators (anti-
CD3 and anti-CD28) were observed in cell cultures from HEU 
neonates born to HIV-infected mothers with uncontrolled HIV 
replication compared to HEU neonates born to HIV-infected 
mothers with undetectable viral load and HU (41).
Other groups used different mitogenic stimuli and reported 
increased proliferative responses among HEU infants to staphy-
lococcal enterotoxin B at 6 and 14 weeks of life (44), and to PHA 
at 6–8 months of life (43) as compared to HU infants. Assessment 
of HEU infant T-cell proliferative responses to BCG vaccination 
have provided discordant results, with no difference at 2 weeks 
(36), weaker response at 6–8 months (43) and at 10 weeks of life 
(36), and stronger response at both 6 and 14 weeks of life (44) 
when comparing HEU infants to HU controls.
Consistency and Controversy of Cell-Mediated 
Immunity Findings
In summary, the most consistent findings are that HEU infants 
have lower CD4 T-cell, lower CD8 T-cell counts, increased acti-
vated and memory T-cells as compared to infants born to HIV-
uninfected women and there is compelling evidence that HEU 
infants have HIV-specific cellular memory response. HIV and 
associated antigenic exposure can take place during gestation. 
Data support that HIV can cross the placenta during gestation as 
HIV has been detected in fetal tissues (60). HIV exposure appears 
to be able to activate HIV-specific memory responses (45–48, 
61). The HIV-specific T-cell immune response, at least in part, 
is suppressed by Treg cells (61). Depletion of Treg cells increased 
HIV-specific T-cell immune responses among HEU infants (61).
It should be noted that there is controversy regarding the 
T-cell response to non-HIV-specific stimulation. Mixed hyper- 
and/or hypo-responsiveness to T-cell activation and the different 
pro-inflammatory cytokines profile may stem from different 
experimental conditions, variable population characteristics, 
maternal HIV viral load, and ARV exposure.
If the HIV-infected in utero milieu leads to priming of the HEU 
immune system, it follows that this takes place in a complex man-
ner. This may be a simplified explanation for the complex reality 
that leads to diversity in HEU hyper- vs. hypo-responsiveness 
TAble 2 | vaccine-induced antibody response in Hiv-exposed uninfected 
infants.
vaccine Main results
Hepatitis B Similar HBsAg IgG levels as compared to HU infants 
following primary vaccination, and antibody levels continued 
to be equivalent through the first 2 years of life (63). The 
majority (>99%) of HEU infants developed sero-protective 
HBsAg IgG levels (64). The prevalence of non-responders 
to HBV among HEU infants is 6.7–11.5% (65–67) and 
comparable to the 5–10% of non-responders reported 
among healthy population
Tetanus toxoid Similar anti-TT IgG levels as compared to HU infants 
following primary vaccination, with the majority of 
HEU infants developing anti-TT IgG seroprotective 
levels (63–65, 68)
Diphtheria toxoid Similar anti-DT IgG levels as compared to HU infants 
following primary vaccination, and 95–99% of HEU infants 
developed anti-DT IgG sero-protective levels (64, 65)
Pneumococcal 
conjugate 
Higher pneumococcal-specific antibody levels as compared 
to HU infants following the second (68) and third 7-valent 
PCV-doses (69)
Haemophilus 
influenzae type B
Similar anti-Hib IgG levels as compared with HU infants, 
following primary vaccination (64, 68) with 91–98% retaining 
protective anti-Hib IgG levels till 2 years of age (63, 70)
Whole cell 
pertussis
Higher anti-pertussis antibody levels as compared with HU 
infants following primary vaccination (63, 64, 68)
Measles Comparable anti-measles antibody levels as compared with 
HU, following one and two measles vaccine doses (63, 71). 
The vast majority (99%) of HEU children had sero-protective 
antibody levels against measles at 7–15 years of age (72)
HBsAg IgG, hepatitis B surface antigen immunoglobulin G; HEU, HIV-exposed 
uninfected; HU, HIV-\unexposed; HBV, hepatitis B vaccine; DTP, diphtheria, tetanus 
toxoid, cellular pertussis vaccines; TT, tetanus toxoid; DT, diphtheria toxoid; PCV, 
pneumococcal conjugate vaccines; Hib, Haemophilus influenzae type b.
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that may be deemed immune dysregulation. It further stands to 
reason that there will be population variation in such immune 
dysregulation, which may explain both discordant results and 
how many HEU infants go on to lead relatively healthy lives com-
pared to some of their peers. Ultimately, it is suspected that for 
some stimuli the afflicted HEU infant will be hyper-responsive, 
while being normal or hypo-responsive to other stimuli.
Humoral immune Response of HeU 
infants to Primary vaccination
The quantity and function of passively acquired maternal anti-
bodies conveyed to HEU infants is reviewed in a companion 
article of this Research Topic by Abu Raya et al. (62). Primary 
vaccination during infancy is of critical importance for preven-
tion of infectious morbidity and mortality. It should be noted 
that the immunogenicity of primary vaccination according 
to the Expanded Program on Immunization (EPI), a World 
Health Organization initiative to expand vaccination programs 
throughout the world, was also evaluated among HEU infants. 
The summarized literature on HEU response to vaccination can 
be found in the following section (Table 2).
Hepatitis B Vaccine
Data on the immunogenicity and seroprotection provided to 
HEU infants following primary immunization with hepatitis B 
vaccine (HBV) suggest that the majority of HEU infants produce 
adequate humoral immune response.
In South Africa, prevaccination (at 2 and 6 weeks) hepatitis 
B surface antigen (HBsAg) IgG levels, presumed maternally 
derived, were significantly higher among HEU than HU infants, 
with one-quarter of HEU infants having sero-protective levels 
(HBsAg IgG > 10 mIU/ml) (63). Following primary vaccination 
according to the EPI, HBsAg IgG levels at 3 months (after two 
HBV doses given at 6 and 10 weeks of age) were similar between 
HEU and HU infants and continued to be equivalent through 
the first 2 years of life (63). A subsequent study of South African 
HEU infants reported that >99% of HEU infants developed sero-
protective antibody levels (HBsAg IgG >10  mIU/ml) 1  month 
after completing the primary HBV series (64). This small South 
African series would suggest that HEU infants do indeed produce 
adequate acquired immunity in response to HBV vaccination.
The prevalence of non-responders to primary series of HBV 
was also described. Among a cohort of Brazilian HEU infants 
vaccinated with HBV (at birth, 1 and 6 months), 6.7% of HEU 
infants were non-responders to HBV (HBsAg IgG <10 mIU/ml) 
1 month after the third dose of HBV (65). This study supports 
earlier findings which reported that about 8% of HEU infants 
did not respond to HBV (66) and more recent data from India 
which found that of HEU infants vaccinated with three doses 
of recombinant HBV (at 6, 10, and 14 weeks), 11.5% were non-
responders 3 months after the third dose of the vaccine (67). The 
reported prevalence of non-responders to HBV among HEU 
infants, 6.7–11.5% (65–67) is comparable to the 5–10% of non-
responders reported among healthy population (73).
In sum, though timing of vaccination and population char-
acteristics are variable, it does appear that the majority of HEU 
infants are capable of mounting a sufficient immune response 
for HBV vaccination to confer adequate seroprotection. What 
remains to be determined is how resilient these responses are and 
whether they wane over time. There may also be a sub-population 
within HEU infants that are at higher risk and do not mount 
adequate immune responses to HBV vaccination.
Tetanus Toxoid Vaccine
Studies that evaluated the immunogenicity and seroprotection 
following tetanus toxoid (TT) vaccination reports that HEU 
infants develop robust immune response. One month following 
the completion of the vaccination series with diphtheria-tetanus 
toxoid-cellular pertussis-Haemophilus influenzae type b (DTP-
Hib) (given at 2, 4, and 6  months) in Brazil, all HEU infants 
showed sero-protective immune response to TT (anti-TT IgG 
>0.1 IU/ml) (65). And following the completion of 3 DTP vac-
cines doses (at 6, 10, and 14 weeks) in South Africa, anti-TT IgG 
levels were similar between HU and HEU infants, and the major-
ity of HEU developed sero-protective levels to TT (63, 64, 68). 
Lowest prevaccination anti-TT IgG levels were associated with 
greatest vaccine-induced immune responses at 16 weeks (68).
Diphtheria Toxoid Vaccine
Data also support that HEU infants mount a quantitative immune 
response to diphtheria toxoid (DT) vaccine that is comparable 
to HU infants. Specifically, Brazilian HEU infants vaccinated 
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with DTP-Hib (at 2, 4, and 6 months) has been shown to have 
similar anti-DT IgG levels compared to infants not exposed to 
HIV, 1 month after the 3rd dose of the vaccine (65). Moreover, 
the percentage of non-responders to DT vaccine (anti-DT IgG 
<0.1 IU/ml) was not significantly different between the groups, 
with 94.7% of HEU subjects and 98.2% of HU infants, having 
protective levels against DT after completion of primary series of 
three DTP doses (65). These findings were supported by a study in 
South Africa that found antibody levels against DT to be similar 
between HEU and HU, 1 month following the completion of pri-
mary vaccination series with diphtheria-toxoid, tetanus-toxoid, 
whole cell pertussis-HibCV (DTwP-HibC) according to the EPI 
(at 6, 10, and 14  weeks) (64). In addition, a high proportion 
(>99%) of HEU children developed sero-protective levels to DT 
vaccine (anti-DT IgG ≥ to 0.01 and 0.1 IU/ml) (64).
Though limited to only two studies on the subject, it appears 
as though HEU infants are not significantly different from peers 
with respect to response to DT vaccine.
Pneumococcal Conjugate Vaccine
Evaluation of the immune response to 7-valent pneumococcal 
conjugate vaccine (PCV) showed higher pneumococcal-specific 
antibody levels following the second (68) and third 7-valent 
PCV-doses (69) in HEU infants as compared to HU controls. 
Specifically, Jones et  al. found that among a cohort of South 
African HEU infants vaccinated with two doses of 7-valent PCV 
(at 6 and 14 weeks), HEU infants had higher levels of pneumo-
coccal-specific antibody levels than HU at 16 weeks of age (68). 
Moreover, infants with the lowest prevaccination pneumococcal-
specific antibody levels had the most robust immune responses 
to the pneumococcal vaccine at 16  weeks (68). However, the 
clinical significance of these robust results is complicated by lack 
of well-established correlate of protection for collective antibody 
response to pneumococcal vaccine (68).
The largest study to date to report the immune response fol-
lowing primary PCV immunization in HEU infants described a 
cohort of HEU infants in South Africa (69). Prevaccination (age 
<6 weeks), HEU infants had lower titers and lower proportion of 
children with serotype-specific anti-capsular antibody ≥0.35 μg/
ml to all serotypes (4, 6B, 9V, 14, 18c, 19F, and 23 F) compared to 
HU infants (69). At 10 weeks, antibody levels following the first 
7-valent PCV-dose (given at age 6  weeks) were lower for four 
serotypes (6B, 14, 19F, and 23F) and the proportion of children 
who had serotype-specific anti-capsular antibody ≥0.35 μg/ml 
were lower for most serotypes (6B, 9V, 14, 19F, and 23F) in HEU 
as compared to HU infants (69). Following the second 7-valent 
PCV-dose (at 10 weeks), the antibody levels measured at 14 weeks 
of age were similar in HEU and HU infants for the majority 
of serotypes (6B, 9V, 14, 18c, 19F, and 23 F) (69). Three to six 
weeks following the third 7-valent PCV-dose (given at 14 weeks), 
the serotype-specific anti-capsular antibody levels were higher 
among HEU infants as compared to HU infants for all serotypes 
(69). When integrated, these data suggest that a two-dose pri-
mary series schedule in HEU children may afford similar protec-
tion against vaccine serotype-specific invasive pneumococcal 
disease as compared to HU children. However, it is noteworthy 
that the functionality of anti-pneumococcal antibodies as a 
correlate of protection is not well founded, and when assessed for 
opsonophagocytic activity there was an absence of consistency in 
the pattern between HEU and HU infants (69).
Haemophilus influenzae Type b Vaccine
Current data on the immunogenicity of Haemophilus influenzae 
type b (Hib) vaccine administered to HEU infants is reassuring 
as HEU infants vaccinated according to the EPI mounted robust 
and immune responses that were similar to HU infants following 
vaccination with Hib vaccine.
Within 1 month following the completion of primary immu-
nization (6, 10, and 14 weeks), South African HEU infants had 
similar anti-Hib antibody levels as compared with HU at the 
age of 16  weeks (64, 68). Gaensbauer et  al. reported findings 
from a cohort of Ugandan HEU infants vaccinated with Hib 
polysaccharide conjugate vaccine at 6, 10, and 14 weeks of age. By 
12 weeks of age (following two Hib vaccine doses), 91% of HEU 
had protective levels (anti-Hib IgG >1.0 μg/ml), as did all infants 
by 24 weeks after three doses. Interestingly, maternally derived 
anti-Hib IgG levels at birth did not correlate with anti-Hib IgG 
levels at 12 or 24 weeks. At 48 weeks, the vast majority (98.3%) of 
HEU still retained protective levels (70).
The duration of HEU infant immune response to primary Hib 
vaccination has been derived from longitudinal studies. Data 
from a South African cohort showed that although prevaccina-
tion anti-Hib IgG levels (at 2 and 6  weeks) were lower among 
HEU compared to HU infants, antibody levels were similar 
between both groups at 3 months (after two doses given at 6 and 
10 weeks) and until 2 years of age (63).
Thus, current data suggest that HEU infants mount immune 
response to Hib vaccine similar to HU infants that lasted until 
2 years of age.
Pertussis Vaccine
Several studies have demonstrated that HEU infants mount 
higher immune response to primary vaccination with whole cell 
pertussis vaccine (given according to the EPI) compared to HU 
infants (63, 64, 68). Jones et al. reported data from a South African 
cohort and found that despite having lower anti-pertussis titers 
at birth, HEU infants had higher anti-pertussis antibody levels 
compared to HU 2 weeks following the completion of primary 
vaccination with thee doses of DTP-Hib vaccine (at 6, 10, and 
14 weeks) (68). Infants with the lowest prevaccination anti-per-
tussis levels exhibited the greatest vaccine responses at 16 weeks 
(68). Reikie et al. has found that at 3 months, anti-pertussis IgG 
levels were similar between South African cohort of HEU and 
HU infants after two doses of DTP vaccine (at 6, 10 weeks), and 
higher for HEU as compared to HU at the age of 6 and 12 months 
(63). Moreover, Simani et  al. reported that 1  month following 
the primary DTP-HibC vaccine series (at 6, 10, and 14 weeks) 
the anti-pertussis-toxoid titers were higher in HEU than in HU 
infants (64). It should be noted that the aforementioned stud-
ies used whole cell pertussis vaccine as compared to acellular 
pertussis vaccine that is currently employed by most developed 
countries. Moreover, the read out measure is critical as measuring 
collective antibody response to multiple antigens (63, 68) might 
be less accurate than antigen-specific responses. The lack of 
TAble 3 | Quantity and function of innate immune system of Hiv-
exposed uninfected infants.
innate immune cell Count and/or function
Neutrophils Count:
– Lower ANCs in HIV/ARV-exposed infants as 
compared to HIV and ARV unexposed infants at 
5 weeks and 8 months of age (74).
– Lower ANCs were associated with ARVs exposure in 
HEU children till 8 years of life (33, 75).
Monocytes Count:
 – Lower monocyte counts in HIV/ARV-exposed infants 
compared to HIV and ARV unexposed infants at 
5 weeks of age (74).
 – Similar proportions of monocytes in HEU as compared 
to HU infants during the first year of life (76).
Function:
 – Enhanced pro-inflammatory response of monocytes 
to bacterial ligand stimulation up to 6 weeks of age in 
HEU as compared to HU infants (76).
Dendritic cells Count:
 – Higher percentage of mDCs in HEU as compared to 
HU newborns at birth but similar proportion of mDCS 
and pDCs during the first 3–12 months (77) and 
during the first year of life (76).
Function:
 – Higher responsiveness of mDCs to stimulation with 
LPS at birth, as compared to HU (77)
 – Enhanced pro-inflammatory response of mDCs to 
bacterial ligand stimulation up to 6 weeks of age, as 
compared to HU (76).
 – Similar response of pDCs to stimulation with CpG 
ODN and similar IFN-α production by pDCs in HEU 
and HU infants at birth (77).
NK cells Count:
 – No difference in the percentage of total NK cells and 
the percentage of different NK cell subsets HEU and 
HU infants at birth (78).
Function:
 – Decline in the percentage of activated and perforin 
positive NK cells among HEU infants over the first 
year of life (78).
ANC, absolute neutrophil counts; HIV, human immunodeficiency virus; ARV, 
antiretroviral; HEU, HIV-exposed uninfected; HU, HIV-Unexposed; ZDV, zidovudine; 
DCs, dendritic cells; mDCs, myeloid dendritic cells; pDCs, plasmacytoid dendritic 
cells; LPS: lipopolysaccharide; CpG ODN, CpG oligodeoxynucleotides; IFN-α, 
interferon-α.
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well-established sero-protective antibody levels is another chal-
lenge for extrapolating these finding to clinical settings. Overall, 
though more data are required on acellular pertussis vaccination 
among HEU infants, it does appear as though HEU infants mount 
satisfactory responses to whole cell pertussis vaccination.
Measles, Mumps, and Rubella Vaccine
Measles vaccine generated both comparable (63) and lower 
immune response (71) among HEU infants as compared to HU 
infants.
The proportion of South African HEU infants with sero-
protective titers against measles was similar compared with HU 
infants, 28 weeks following the first measles vaccine dose (admin-
istered at nearly 40 weeks of age) and 2 weeks after the booster 
dose (administered at nearly 68  weeks of age) (71). However, 
waning immunity in HEU was noticed 9.5 months post booster, 
when HU had higher anti-measles titers and were more likely to 
have seroprotective titers (94.3%) compared with HEU (79.6%) 
infants, bringing the durability of HEU immune response into 
question (71). In contrast to the previous findings, the average 
levels of anti-measles virus antibodies were nearly indistinguish-
able between South African HEU and HU infants prevaccination 
(at 2 and 6 weeks), at 12 months (post 1st vaccine dose given at 
age of 9 months) and at 2 years (post 2nd vaccine dose given at 
18 months) (63).
The long-term vaccine-induced immune memory against 
measles, rubella, and mumps was recently explored (72). A large 
US cohort of HEU children was evaluated at the age of 7–15 years, 
among which 87% of HEU infants had received two doses of 
measles, mumps, and rubella vaccine. The prevalence of measles 
seroprotection, rubella seroprotection, and mumps seropositivity 
were 99, 98, and 97%, respectively (72). Thus, although limited to 
one study, it appears that HEU infants retain long-term immunity 
to the measles, mumps, and rubella vaccine.
iNNATe iMMUNe SYSTeM OF HeU 
iNFANTS
The innate immune system is the immediate, first line of defense 
against infectious agents that react rapidly upon encountering a 
pathogen. It is composed of different cells, including neutrophils, 
dendritic cells (DCs), monocytes, and natural killer (NK) cells.
In the 1980s, in vitro data showed that the development of the 
innate immune system can be impacted by ARVs as ZDV has 
been shown to suppress hematopoietic stem cells progenitors of 
granulocyte and macrophages (27). Several studies followed and 
evaluated the quantity and the function of innate immune system 
cells of HEU infants (Table 3).
Neutrophils
HIV and ARVs exposed infants have lower neutrophil counts than 
HIV and ARVs unexposed infants (74). Data suggest that suppres-
sion of hematopoietic stem cell progenitors is the most plausible 
mechanism as reduced neutrophil levels have been shown to be 
non-immune mediated (74) and ARV exposure has been shown 
to affect two other lineages (platelets and lymphocytes) (79, 80).
The dynamics of neutrophil counts over time was described. 
In HIV and ARV-exposed infants (90/92 confirmed HEU), 
neutrophil levels were lower than in HIV and ARV unexposed 
infants from birth until 20 months of age, reaching statistical 
significance at 5  weeks and 8  months (74). In another study, 
neutrophil levels of HEU subjects, although not compared to 
HU controls, were high shortly after birth, declining to reach a 
nadir at 2 months, then increasing until approximately 7 months; 
after this, the increase was more gradual before stabilizing at 
3.5 years (75).
Exposure to ARVs is associated with decrease in neutrophil 
levels lasting till 18 months of age (33) and up to 8 years of age 
in another study (75). Thus, it appears that ARV exposure have 
a long-term effect on neutrophil counts. However, whether 
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this long-term effect is affected by the timing of ARV exposure 
(in utero, neonatal or both) has not been established yet.
Dendritic Cells
Circulating DCs are human antigen-presenting cells (APC) and 
are the precursors of tissue and lymphoid organ DCs; conven-
tional DCs [cDCs, also known as myeloid DCs (mDCs)] and 
plasmacytoid DC (pDC) are the two main subsets of human DCs. 
Both cell types mediate the downstream immune response based 
on the cytokines they secrete (81).
Few studies described the frequency and function of DCs 
among HEU infants. HEU newborns are reported as having a 
higher percentage of mDCs than HU newborns at birth in one 
study (77), but all other currently available data suggest that HEU 
and HU infants have similar proportion of cDCS and pDCs during 
the first 3–12 months (77) and during the first year of life (76). It 
must be noted that these reports were based on proportion rather 
than absolute count; thus, it is at this time inconclusive whether 
DCs counts are affected by perinatal ARV and HIV exposure.
Data on the function of DCs among HEU infants are also 
limited, and is based on reports of in vitro study of TLR agonists 
and cytokine responses.
At birth, mDCs of HEU infants exhibited higher responsive-
ness to stimulation with LPS (via TLR4) than HU (77). As com-
pared to HU, a greater proportion of HEU mDCs responded to 
bacterial ligand stimulation (PAM via TLR1/2 and LPS via TLR4) 
by secretion of pro-inflammatory cytokines (TNF-alpha, IL-6, 
IL-12) up to 6 weeks of age (76). Beyond 6 weeks and until 1 year 
of age, the response of mDCs to bacterial ligands was comparable 
between HEU and HU infants (76).
At birth, pDCs of HEU and HU responded similarly to CpG 
ODN stimulation (via TLR9) (77) and secreted similar levels of 
IFN-α, indicating a normal stimulated pDC function (77). In 
another study, a comparable proportion of pDCs that responded 
to bacterial ligands by secretion of inflammatory cytokines were 
reported among HEU and HU infants until 1 year of age (76).
Taken together, existing data suggest that gestational HIV-1 
exposure increases HEU infants’ mDCs responsiveness at birth 
and enhances a pro-inflammatory response to bacterial ligand 
stimulation up to 6 weeks of life that normalizes by 1 year of age. 
This is limited to only a pair of studies and the clinical significance 
of these findings is yet unknown.
Monocytes
Limited data exists on the quantity and function of monocytes 
among HEU infants. Monocyte counts were lower in the HIV- and 
ARV-exposed infants than in unexposed controls from birth until 
8 months of age, reaching statistical significance at 5 weeks of age 
(74). However, in another study, the proportions of monocytes in 
HEU as compared to HU infants were not statistically different 
during the first year of life (76). The difference in absolute levels 
(74) of monocytes might have stronger clinical implications that 
the reported proportion (76).
Monocyte activity has been assayed though whole blood 
response to different TLR ligands, and has revealed differences 
between HEU and HU monocyte cytokine production during 
only the first 6 months of life (71). Specifically, a higher proportion 
monocytes from HEU infants mounted pro-inflammatory 
cytokine response (TNF-α, IL-6, IL-12) to bacterial ligands 
(PAM via TLR1/2 and LPS via TLR4) as compared to HU (76). 
Conversely, HU infants’ monocytes responded more strongly to 
viral ligand stimulation (pI:C and R848) at 6 months. By 1 year 
of age, the differences in the innate immune system activation 
between HEU and HU monocytes completely disappeared (76). 
This study suggest that HEU monocytes may be affected in 
function, leading to stronger immune response toward bacterial 
threats at the cost of weaker viral responses during early life, yet 
this stands to be repeated and tested further.
NK Cells
Natural killer cells are directly cytotoxic, often to virally infected 
cells, and do not require guidance by other cells. Currently, there 
is very limited data on the quantity and function of NK cells 
among HEU as compared to HU infants. At birth, the percentage 
of total NK cells and the percentage of different NK cells subsets 
(CD56 bright, CD56+ CD16+, CD56− CD16+) was not signifi-
cantly different between HEU and HU infants. The total NK cell 
percentage did not change significantly in both HEU and HU 
over the first year of life (78).
Functional comparison demonstrated a significant decline in 
the percentage of activated NK cells (CD56dim subset) and perforin 
positive NK cells among HEU infants over the first year of life 
(78). By contrast, over time HU infants demonstrated an increase 
in perforin positive NK cells, a marker of cytolytic potential (78). 
The poor expression of perforin among HEU infants might have 
clinical implications as it might compromise the ability of HEU 
infants to control viral infection (78).
CONClUDiNG ReMARKS
Current evidence suggests that during early life, the developing 
immune system of HEU infants differs from HU peers. The etiol-
ogy of this altered immune ontogeny appears to be multifactorial, 
including in utero exposure to ARVs, HIV antigens and/or other 
antigens related to other infections in HIV-infected mothers. 
Few longitudinal studies describe their dynamics over time. 
Although HEU infants are at increased risk for infectious disease 
morbidity and mortality, their quantitative humoral immune 
response to primary vaccination is adequate. This suggests that 
other mechanisms, including impaired qualitative antibody 
response, altered CMI, impaired innate immunity or infections 
caused by pathogens other than those covered by existing vac-
cines may be at the heart of increased morbidity and mortality 
of HEU infants. Transient innate immune system activation 
leading to enhanced pro-inflammatory response to bacterial 
ligands stimulation or immune tolerance to viral ligands has 
been reported among HEU infants. The origins of this innate 
immune system activation might stem from increased infection 
or inflammation of the uterine environment that exposes the 
developing immune system of the neonate with antigen and a 
potentially pro-inflammatory milieu. This has the potential to 
prime the neonatal immune system in utero. The idea of priming 
of the innate immune system is supported by recent evidence 
on memory of the innate immune system (82). Whether the 
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postnatal differential pathogen-specific innate immune cells 
activation affects the susceptibility of HEU infants to severe 
infections should be further investigated.
Synthesizing a clear model for the changes of the developing 
immune system is challenging as studies have enrolled different 
HEU population at different ages; HEU subjects were exposed to 
different maternal viral loads and ARV regimens; the laboratory 
methods employed, the experimental conditions and the read out 
measurements were also different among studies. These studies 
still do have merit, as they do suggest that the perinatal environ-
ment may lead to an altered immune system.
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